Sexual DysfunctionNCT04015037
The Effect of Non-hormonal Gel Application in Women in the Menacme With Sexual Dysfunction
A study of Sexual Dysfunction, run by JULIANA AQUINO DE MOURA.
Trial summary
The aim of the present randomized, double-blind study is to evaluate the effects of a vulvar, moisturizing, non-hormonal gel containing visnadine, ethil ximeninate, Coleus barbatus and Panicum miliaceum (TROFIS (R)), in women in the menacme, regarding the sexual response measured by the Female Sexual Function Index… Read more about this study
- Who is it for?
- Ages 20 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Sexual Dysfunction
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2015to 10 Dec 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- women with age greater than 20, in the menacme, with complaints about sexual activity.
Who cannot join
- body mass index (BMI) greater than 30
About this study
Official title: Double-blind Randomized Study on the Effect of Non-hormonal Gel Application to the Genital Area of Women in the Menacme With Sexual Dysfunction
The aim of the present randomized, double-blind study is to evaluate the effects of a vulvar, moisturizing, non-hormonal gel containing visnadine, ethil ximeninate, Coleus barbatus and Panicum miliaceum (TROFIS (R)), in women in the menacme, regarding the sexual response measured by the Female Sexual Function Index (FSFI) when compared to placebo.
Read the detailed description
In this study, 60 sexually active (having a male partner, boyfriend or husband) female volunteers will be included. All patients will undergo gynecological evaluation of the vulvar area and the vaginal mucosa before and after the treatment, by means of visual inspection and speculum examination.
Volunteers will be requested to apply once a day, for four weeks, a small amount of gel to the dry area (vulva), followed by a gentle massage to promote the absorption of the product.
For the time of the study, volunteers will be asked not to change personal hygiene products, e.g., moisturizers, soaps, deodorants, etc. Volunteers will be instructed to fill out the "diary of use" with the dates of product application and notes about feelings of discomfort or subjective reactions, if any. In the final visit, volunteers will answer the FSFI questionnaire (see Annex 1). All variables in the questionnaire (comfort during sexual intercourse, hydration and softness of genital tissue) will undergo a descriptive analysis.
In the first moment of the study, patients will receive the FSFI (Female Sexual Function Index) questionnaire, self-applied and validated for the Portuguese language in Brazil (Thiel et al., 2008). Then, the estronization of external genital organs will be assessed by gynecological exam.
Patients will be randomly assigned to four groups: group A and B (A and B - 30 and 30 patients in the menacme, following the order defined by the computer-generated randomization list.
During the advertising process, patients will be interviewed by phone following the same chronological order of their contacts with the clinic and a medical evaluation will be scheduled.
The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion.
After collection of clinical history and gynecological anamnesis, these women will undergo a general physical examination and gynecological examination, oncotic cytology, and imaging examination of the endometrial thickness (transvaginal ultrasonography). With the exams results, the women will undergo another medical evaluation.
All participants will sign the Informed Consent Form (ICF). Patients in the menacme _ Group A and B (medicated or placebo) Biolab Farmaceutica (242 Rua das Olimpíadas, 3rd floor, Vila Olímpia/São Paulo - SP) will provide free of charge Trofis and placebo (inactive compound) gels. All tubes containing the gel will have the same shape and will be labeled with a batch number, which carries the information on the content, only known by Biolab. In this manner, blindness will be maintained for the entire study time, until the last patient finishes one month of treatment. Patients and the physician researcher will not know which gel contains the active component or to which group it belongs. The volunteers will apply once a day, for four weeks, a small amount of gel to the dry area (vulva), followed by a gentle massage to promote the absorption of the product.
In the end of the first month of treatment, patients will go to the clinic for a follow up to ensure treatment adherence and to evaluate potential adverse effects of the gel. After one month of treatment, patients will answer the FSFI questionnaire again, and will undergo a general clinical examination and gynecological examination of the external genital organs.
In the end of treatment and with results of complementary exams, patients will be instructed to continue attending the gynecological routine consultations in the Ginecologia Endócrina, outpatient clinic of EPM/UNIFESP.
- Conditions
- Sexual Dysfunction
- Being tested
- placebo or drug
- Medical subject headings
- Sexual Dysfunction, Physiological
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placebo or drugCombination product
Group A and B (medicated or placebo)
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion Receives: Combination Product: placebo or drug |
| Group B | Experimental | The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion Receives: Combination Product: placebo or drug |
What is being measured
The primary outcome is the main question the study is designed to answer.
improvement of sexual desire
The aim of the present randomized, double-blind study is to evaluate the effects of a vulvar, moisturizing, non-hormonal gel containing visnadine, ethil ximeninate, Coleus barbatus and Panicum miliaceum (TROFIS (R)), in women in the menacme, regarding the sexual response measured by the Female Sexual Function Index (FSFI) when compared to placebo.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2019
- Study start20 Oct 2015
- Primary completion10 Dec 2016
- Study completion10 Dec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sexual DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized double-blind placebo-controlled study with women with age greater than 20, in the menacme, with complaints about sexual activity.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- JULIANA AQUINO DE MOURA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, JULIANA AQUINO DE MOURA, Federal University of São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04015037
- Sponsor's protocol ID
- 933.092
- Status last verified
- Jul 2019
- First submitted
- 29 Nov 2017
- Last updated
- 10 Jul 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: do not aplay
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Double-blind Randomized Study on the Effect of Non-hormonal Gel Application to the Genital Area of Women in the Menacme With Sexual Dysfunction
- ClinicalTrials.gov ID
- NCT04015037
- Acronym / sponsor ID
- 933.092
- Conditions
- Sexual Dysfunction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- JULIANA AQUINO DE MOURAUniversity, hospital or other
- Study start
- 20 Oct 2015 (actual)
- Primary completion
- 10 Dec 2016 (actual)
- Study completion
- 10 Dec 2016 (actual)
- First posted
- 10 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present randomized, double-blind study is to evaluate the effects of a vulvar, moisturizing, non-hormonal gel containing visnadine, ethil ximeninate, Coleus barbatus and Panicum miliaceum (TROFIS (R)), in women in the menacme, regarding the sexual response measured by the Female Sexual Function Index (FSFI) when compared to placebo.
Detailed description
In this study, 60 sexually active (having a male partner, boyfriend or husband) female volunteers will be included. All patients will undergo gynecological evaluation of the vulvar area and the vaginal mucosa before and after the treatment, by means of visual inspection and speculum examination.
Volunteers will be requested to apply once a day, for four weeks, a small amount of gel to the dry area (vulva), followed by a gentle massage to promote the absorption of the product.
For the time of the study, volunteers will be asked not to change personal hygiene products, e.g., moisturizers, soaps, deodorants, etc. Volunteers will be instructed to fill out the "diary of use" with the dates of product application and notes about feelings of discomfort or subjective reactions, if any. In the final visit, volunteers will answer the FSFI questionnaire (see Annex 1). All variables in the questionnaire (comfort during sexual intercourse, hydration and softness of genital tissue) will undergo a descriptive analysis.
In the first moment of the study, patients will receive the FSFI (Female Sexual Function Index) questionnaire, self-applied and validated for the Portuguese language in Brazil (Thiel et al., 2008). Then, the estronization of external genital organs will be assessed by gynecological exam.
Patients will be randomly assigned to four groups: group A and B (A and B - 30 and 30 patients in the menacme, following the order defined by the computer-generated randomization list.
During the advertising process, patients will be interviewed by phone following the same chronological order of their contacts with the clinic and a medical evaluation will be scheduled.
The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion.
After collection of clinical history and gynecological anamnesis, these women will undergo a general physical examination and gynecological examination, oncotic cytology, and imaging examination of the endometrial thickness (transvaginal ultrasonography). With the exams results, the women will undergo another medical evaluation.
All participants will sign the Informed Consent Form (ICF). Patients in the menacme _ Group A and B (medicated or placebo) Biolab Farmaceutica (242 Rua das Olimpíadas, 3rd floor, Vila Olímpia/São Paulo - SP) will provide free of charge Trofis and placebo (inactive compound) gels. All tubes containing the gel will have the same shape and will be labeled with a batch number, which carries the information on the content, only known by Biolab. In this manner, blindness will be maintained for the entire study time, until the last patient finishes one month of treatment. Patients and the physician researcher will not know which gel contains the active component or to which group it belongs. The volunteers will apply once a day, for four weeks, a small amount of gel to the dry area (vulva), followed by a gentle massage to promote the absorption of the product.
In the end of the first month of treatment, patients will go to the clinic for a follow up to ensure treatment adherence and to evaluate potential adverse effects of the gel. After one month of treatment, patients will answer the FSFI questionnaire again, and will undergo a general clinical examination and gynecological examination of the external genital organs.
In the end of treatment and with results of complementary exams, patients will be instructed to continue attending the gynecological routine consultations in the Ginecologia Endócrina, outpatient clinic of EPM/UNIFESP.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Randomized double-blind placebo-controlled study with women with age greater than 20, in the menacme, with complaints about sexual activity.
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Combination Product: placebo or drugThe participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion |
| Group B | Experimental | Combination Product: placebo or drugThe participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- women with age greater than 20, in the menacme, with complaints about sexual activity.
Key exclusion criteria (1 listed)
- body mass index (BMI) greater than 30
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placebo or drugGroup A and B (medicated or placebo) | Combination product | Group A, Group B |
Primary outcome
improvement of sexual desire
Time frame: 30 days
The aim of the present randomized, double-blind study is to evaluate the effects of a vulvar, moisturizing, non-hormonal gel containing visnadine, ethil ximeninate, Coleus barbatus and Panicum miliaceum (TROFIS (R)), in women in the menacme, regarding the sexual response measured by the Female Sexual Function Index (FSFI) when compared to placebo.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2019.
- Individual participant dataSharing planned: No. do not aplay
Related trials for Sexual Dysfunction
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Recruiting
PRP for Sexual Function
Female Sexual Dysfunction, Sexual Dysfunction
Recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
RecruitingPhase 4
Assessment of the Value of FAPI and FDG-PET-CT in Diagnosis of Acute Phase Peyronie's Disease
Peyronie's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study of Sexual Dysfunction, run by JULIANA AQUINO DE MOURA.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improvement of sexual desire (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2019.